368 related articles for article (PubMed ID: 8198984)
1. p53 mutations and overexpression in locally advanced breast cancers.
Faille A; De Cremoux P; Extra JM; Linares G; Espie M; Bourstyn E; De Rocquancourt A; Giacchetti S; Marty M; Calvo F
Br J Cancer; 1994 Jun; 69(6):1145-50. PubMed ID: 8198984
[TBL] [Abstract][Full Text] [Related]
2. A novel p53 mutation hotspot at codon 132 (AAG-->AGG) in human renal cancer.
Dahiya R; Deng G; Selph C; Carroll P; Presti J
Biochem Mol Biol Int; 1998 Feb; 44(2):407-15. PubMed ID: 9530523
[TBL] [Abstract][Full Text] [Related]
3. Detecting p53 gene mutation of breast cancer and defining differences between silver staining PCR-SSCP and immunohistochemical staining.
Ryu JW; Lee MC; Jang WC
J Korean Med Sci; 2000 Feb; 15(1):73-7. PubMed ID: 10719813
[TBL] [Abstract][Full Text] [Related]
4. P53 in breast carcinomas: association between presence of mutation and immunohistochemical expression using a semiquantitative approach.
Schmitt FC; Soares R; Cirnes L; Seruca R
Pathol Res Pract; 1998; 194(12):815-9. PubMed ID: 9894246
[TBL] [Abstract][Full Text] [Related]
5. Abnormalities of the p53 MDM2 and DCC genes in human leiomyosarcomas.
Patterson H; Gill S; Fisher C; Law MG; Jayatilake H; Fletcher CD; Thomas M; Grimer R; Gusterson BA; Cooper CS
Br J Cancer; 1994 Jun; 69(6):1052-8. PubMed ID: 8198970
[TBL] [Abstract][Full Text] [Related]
6. Correlation between p53 immunostaining patterns and gene sequence mutations in breast carcinoma.
Visscher DW; Sarkar FH; Shimoyama RK; Crissman JD
Diagn Mol Pathol; 1996 Sep; 5(3):187-93. PubMed ID: 8866232
[TBL] [Abstract][Full Text] [Related]
7. P53 tumour-suppressor gene mutations are mainly localised on exon 7 in human primary and metastatic prostate cancer.
Dahiya R; Deng G; Chen KM; Chui RM; Haughney PC; Narayan P
Br J Cancer; 1996 Jul; 74(2):264-8. PubMed ID: 8688333
[TBL] [Abstract][Full Text] [Related]
8. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion.
Moll UM; Riou G; Levine AJ
Proc Natl Acad Sci U S A; 1992 Aug; 89(15):7262-6. PubMed ID: 1353891
[TBL] [Abstract][Full Text] [Related]
9. Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value.
Kovach JS; Hartmann A; Blaszyk H; Cunningham J; Schaid D; Sommer SS
Proc Natl Acad Sci U S A; 1996 Feb; 93(3):1093-6. PubMed ID: 8577720
[TBL] [Abstract][Full Text] [Related]
10. Mutation of tumor suppressor gene p53 is frequently found in vulvar carcinoma cells.
Hietanen SH; Kurvinen K; Syrjänen K; Grénman S; Carey T; McClatchey K; Syrjänen S
Am J Obstet Gynecol; 1995 Nov; 173(5):1477-82. PubMed ID: 7503188
[TBL] [Abstract][Full Text] [Related]
11. The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry.
Sjögren S; Inganäs M; Norberg T; Lindgren A; Nordgren H; Holmberg L; Bergh J
J Natl Cancer Inst; 1996 Feb; 88(3-4):173-82. PubMed ID: 8632491
[TBL] [Abstract][Full Text] [Related]
12. p53 mutations and histological type of invasive breast carcinoma.
Marchetti A; Buttitta F; Pellegrini S; Campani D; Diella F; Cecchetti D; Callahan R; Bistocchi M
Cancer Res; 1993 Oct; 53(19):4665-9. PubMed ID: 8402644
[TBL] [Abstract][Full Text] [Related]
13. Novel pattern of P53 mutation in breast cancers from Austrian women.
Hartmann A; Rosanelli G; Blaszyk H; Cunningham JM; McGovern RM; Schroeder JJ; Schaid DJ; Kovach JS; Sommer SS
J Clin Invest; 1995 Feb; 95(2):686-9. PubMed ID: 7598762
[TBL] [Abstract][Full Text] [Related]
14. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
[TBL] [Abstract][Full Text] [Related]
15. High frequency and heterogeneous distribution of p53 mutations in aflatoxin B1-induced mouse lung tumors.
Tam AS; Foley JF; Devereux TR; Maronpot RR; Massey TE
Cancer Res; 1999 Aug; 59(15):3634-40. PubMed ID: 10446974
[TBL] [Abstract][Full Text] [Related]
16. Ki-ras and p53 mutations in pancreatic ductal adenocarcinoma.
Rall CJ; Yan YX; Graeme-Cook F; Beauchamp R; Yandell DW; Povoski SP; Rustgi AK
Pancreas; 1996 Jan; 12(1):10-7. PubMed ID: 8927612
[TBL] [Abstract][Full Text] [Related]
17. Correlation between p53 mutations and antibody staining in breast carcinoma.
Dunn JM; Hastrich DJ; Newcomb P; Webb JC; Maitland NJ; Farndon JR
Br J Surg; 1993 Nov; 80(11):1410-2. PubMed ID: 8252351
[TBL] [Abstract][Full Text] [Related]
18. p53 mutations and expression in ovarian cancers: correlation with overall survival.
Wen WH; Reles A; Runnebaum IB; Sullivan-Halley J; Bernstein L; Jones LA; Felix JC; Kreienberg R; el-Naggar A; Press MF
Int J Gynecol Pathol; 1999 Jan; 18(1):29-41. PubMed ID: 9891239
[TBL] [Abstract][Full Text] [Related]
19. p53 immunoreactivity and single-strand conformational polymorphism analysis often fail to predict p53 mutational status.
Tolbert DM; Noffsinger AE; Miller MA; DeVoe GW; Stemmermann GN; Macdonald JS; Fenoglio-Preiser CM
Mod Pathol; 1999 Jan; 12(1):54-60. PubMed ID: 9950163
[TBL] [Abstract][Full Text] [Related]
20. p53 mutations are confined to the comedo type ductal carcinoma in situ of the breast. Immunohistochemical and sequencing data.
O'Malley FP; Vnencak-Jones CL; Dupont WD; Parl F; Manning S; Page DL
Lab Invest; 1994 Jul; 71(1):67-72. PubMed ID: 8041120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
